1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. AUROBINDO PHARMA LTD.
Aurobindo Pharma Ltd.
NSE: AUROPHARMA | BSE: 524804

Aurobindo Pharma Live Share Price Today, Share Analysis and Chart

Strong Performer, Getting Expensive
BasketIn 5 Starfolio Baskets
aboutAurobindo Pharma Limited is an integrated pharmaceutical company with a market-leading position in generics and active pharmaceutical ingredients (APIs). As the second-largest listed Indian pharmaceutical company by revenue, it operates across 150+ c... Read More
Ask AI about Aurobindo Pharma
1681.4021.50(1.30%)

Near 52W High of ₹1740.00

967.4K
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Board Meeting
The next board meeting for Aurobindo Pharma is on 04 Nov 2026 for the purpose of Quarterly Results & Interim Dividend See details
Loading...
- / 100
- / 100
60.4 / 100
Strong Performer, Getting ExpensiveThese stocks are strong in quality and technicals but have medium valuation. At somewhat expensive valuations, investors should be cautious before buyingView SimilarEmbed DVM
Analyst Price Target
-

27

S

4

W

7

O

2

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

15Positive8Negative

Pass in checklist65.2%

045
55
100

PE Valuation Check

Right Now
Overvalued
-16.9%
1 Year Forward
Fairly Valued
-1.6%
INSIGHTAurobindo Pharma is overvalued at current PE, but fairly valued on future earnings estimates

Aurobindo Pharma Stock Price Analysis

Day Price Range

1.3% 1 Day return
1681.4 (LTP)
1,647.21,687
LowHigh

Week Price Range

7.0% 1 Week return
1681.4 (LTP)
1,5531,687
LowHigh

Month Price Range

0.6% 1 Month return
1681.4 (LTP)
1,547.71,715
LowHigh

52 Week Price Range

47.6% 1 Year return
1681.4 (LTP)
1,1061,740
LowHigh
View full Price History/Seasonality

Aurobindo Pharma Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Hit

Aurobindo Pharma's Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

CURRENT EPS
60.3
AVG. ESTIMATE
81.2
LOW ESTIMATE
73
HIGH ESTIMATE
91.5
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 34.6% in FY27

Consensus Recommendation

26 ANALYST Recommendations
BUY

The consensus recommendation from 26 analysts for Aurobindo Pharma is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Aurobindo Pharma Technical Analysis

Aurobindo Pharma EMA & SMA

Bullish+8
8 bullish, 0 bearish
Bullish8
Bearish0
5 Day1650.0
10 Day1642.6
12 Day1643.3
20 Day1649.1
26 Day1651.8
50 Day1645.7
100 Day1597.0
200 Day1495.6

Aurobindo Pharma Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202657.2%
Week57.8%
Month56.0%

Aurobindo Pharma Active Candlesticks

Long Line Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Aurobindo Pharma Resistance and Support

1671.87
Pivot
First Resistance1696.5
Second Resistance1711.7
Third Resistance1736.3
First Support1656.7
Second Support1632.1
Third Support1616.9
Day RSI54.8
Day MACD-8.5
Day MFI46.7
Day MACD Signal Line-10.9

Aurobindo Pharma Beta

1 Month0.8
1 Year0.4
3 Month0.3
3 Year0.7

Aurobindo Pharma Price Change Analysis

↑0.6%
Over 1 Month
LowHigh
1547.71715
↑6.4%
Over 3 Months
LowHigh
1536.81740
↑21.0%
Over 6 Months
LowHigh
13671740
↑47.6%
Over 1 Year
LowHigh
11061740
All Technicals →

Aurobindo Pharma Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Rpr Sons Advisors Private Limited, Mrs.P.Suneela Rani (Jointly Holding)Promoter192,997,92333.5 %
Quant Mutual Fund - Quant Arbitrage FundDii28,265,6634.9 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Aurobindo Pharma Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
GOLDMAN SACHS (SINGAPORE) PTE.- ODIBlockSell16 Oct 20251107106,228NSE
GOLDMAN SACHS BANK EUROPESE - ODIBlockPurchase16 Oct 20251107106,228NSE
SOCIETE GENERALEBlockSell25 Jan 20241160.10107,558NSE
MARSHALL WACE INVESTMENT STRATEGIES TOPS FUNDBlockPurchase25 Jan 20241160.1044,921NSE
MARSHALL WACE INVESTMENT STRATEGIES MARKET NEUTRAL TOPS FUNDBlockPurchase25 Jan 20241160.108,134NSE
MARSHALL WACE INVESTMENT STRATEGIES EUREKA FUNDBlockPurchase25 Jan 20241160.1053,641NSE
MARSHALL WACE INVESTMENT STRATEGIES SYSTEMATIC ALPHA PLUS FUNDBlockPurchase25 Jan 20241160.10862NSE
BNP PARIBAS ARBITRAGEBlockSell25 Jan 20241160.101,484,323BSE
BNP PARIBAS ARBITRAGEBlockSell25 Jan 20241160.10150,001BSE
SOCIETE GENERALEBlockPurchase25 Jan 20241160.101,484,323BSE
All deals
All insider trades

Aurobindo Pharma Corporate Actions

Aurobindo Pharma Dividend history and yield

Aurobindo Pharma dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Aurobindo Pharma dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
108 Aug 2025
4INTERIM08 Aug 2025Equity Share
220 Feb 2024
1.5INTERIM20 Feb 2024Equity Share
320 Nov 2023
3INTERIM20 Nov 2023Equity Share
417 Feb 2023
3INTERIM17 Feb 2023Equity Share
506 Jun 2022
4.5INTERIM07 Jun 2022Equity Share

Aurobindo Pharma Bonus shares

Aurobindo Pharma bonus history along with announcement, record, ex-bonus dates, and bonus ratios.

#Ex-Date
Bonus RatioRecord Date
120 Jul 2015
1:121 Jul 2015
207 Mar 2000
1:101 Apr 2000

Aurobindo Pharma Board Meetings

Aurobindo Pharma past and upcoming board meetings.

#Ex-Date
PurposeNotes
104 Nov 2026
Quarterly Results & Interim Dividend-
205 Aug 2026
Quarterly Results-
321 May 2026
Audited Results-
406 Apr 2026
Buy Back of Shares-
509 Feb 2026
Quarterly Results-

Aurobindo Pharma Stock Split

Aurobindo Pharma stock split details, including announcement, record, and ex-split dates, along with the split ratios

#Ex-Date
Old FVNew FVRecord Date
110 Feb 2011
5111 Feb 2011
223 Oct 2003
10531 Oct 2003
All Corporate Actions

Aurobindo Pharma Research Reports

Aurobindo Pharma research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
106 Aug 2026Deven Choksey
Target
17581588.9Accumulate10.64%5.82%pdf
205 Aug 2026Motilal Oswal
Target
18601588.9Buy17.06%5.82%pdf
331 May 2026Deven Choksey
Target
14441426.4Hold1.23%17.88%pdf
424 May 2026Prabhudas Lilladhar
Reco
Target
14001454.6Hold-3.75%15.59%pdf
521 May 2026BOB Capital Markets Ltd.
Target
16861463.5Buy15.2%14.89%pdf
All Reports of Aurobindo

Aurobindo Pharma Corporate Filings

Aurobindo Pharma BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
26 Oct 2026
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Earnings Call scheduled to be held on November 5, 2026 at 8:30 AM (IST) on Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2026.
PDF
26 Oct 2026
Aurobindo Pharma Ltd - 524804 - Board Meeting Intimation for Intimation Of Board Meeting
Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Intimation of Board Meeting scheduled to be held on November 4, 2026 inter alia to consider and approve Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2026, and Payment of Interim Dividend, if any, for the financial year 2026-27.
PDF
09 Oct 2026
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of Notice published in newspapers.
PDF
05 Oct 2026
Aurobindo Pharma Ltd - 524804 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Submission of certificate in terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
PDF
03 Oct 2026
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Submission of Press Release that is being issued by the Company in connection with receipt of USFDA final approval for Perampanel Tablets 2 mg, 4 mg, 6 mg, 8 mg 10 mg and 12 mg.
PDF
VIEW ALL

Aurobindo Pharma DocumentsAsk MarketMind AI

Aurobindo Pharma Earnings Call

Aurobindo Pharma earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
13 Aug 2026Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
27 May 2026Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
16 Feb 2026Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
11 Nov 2025Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAi summaryLink
08 Aug 2025Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAi summaryLink
view all

Aurobindo Pharma Annual Reports

Aurobindo Pharma financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Aurobindo Pharma Credit Ratings

Aurobindo Pharma credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
09 Jun 2026india ratingsIndia Ratings Affirms Aurobindo Pharma’s Bank Facilities at ‘IND AA+’; Outlook StableLink
10 Mar 2025india ratingsIndia Ratings Affirms Aurobindo Pharma’s Bank Facilities at ‘IND AA+’; Outlook StableLink
19 Dec 2023india ratingsIndia Ratings Affirms Aurobindo Pharma’s Bank Facilities at ‘IND AA+’; Outlook Stable Link
19 Oct 2023india ratingsIndia Ratings Discontinues Voluntary Issuer Rating Disclosure due to Regulatory Requirements; All Outstanding Instrument Rating Remain Unaffected for Aurobindo Pharma LtdLink
19 Oct 2022india ratingsIndia Ratings Affirms Aurobindo Pharma at ‘IND AA+’; Outlook StableLink

Aurobindo Pharma Investor Presentations

Aurobindo Pharma investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
05 Aug 2026Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
21 May 2026Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
10 Feb 2026Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
09 Feb 2026Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
05 Nov 2025Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Aurobindo Pharma - Company Profile

Aurobindo Pharma Management Structure

Aurobindo Pharma management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Mr.Tvijay KumarPresident(FRD)-Mar 26
Mr. A.V.S.Murali MohanVice President-Mar 26
Mr. Ilapakurty S R . Chandra RaoSenior Vice President-Mar 26
Dr. U.N.B. RajuSenior Vice President-Mar 26
Dr. K. Rama SrinivasAssociate President-Mar 26
Mr. S.V.S.S.S.PrasadSenior Vice President-Mar 26
Mr. P. ShashikumaranAssociate President-Mar 26
Dr. Hemant Kumar SharmaPresident(Business Unit)-Mar 26
Dr. Parveen Kumar LuthraChief Scientific Officer-Mar 26
B Adi ReddyCompany Secretary,Compliance Officer-Mar 26
Mr. S. SubramanianChief Financial Officer-Mar 26
Mr. Mohammed. AmjadAssociate Vice President-Mar 26
Mr. Mula Surya Narayana MurthySenior Vice President(Accounts)-Mar 26
Mr. Kandi S ChandrashekharAssociate President(FRD)-Mar 26
Mr. Roopak SawhneyAssociate President-Mar 26
Dr. Gita RaoPresident-Mar 26
Mr.V. Naga PrasadChief Scientific Officer-Mar 26
Mr. A.V.S. MallikharjunaAssociate President(Operations)-Mar 26
Mr. Godi Bhaskara ReddyAssociate President(Operations)-Mar 26
Dr. K Suresh KumarAssociate President(Human Resources)-Mar 26
Mr. P. Srinivasa ReddyAssociate President(Corporate Engineering)-Mar 26
Mr. A. Rama Mohana RaoChief Quality Officer-Mar 26

Aurobindo Pharma Board of Directors

Aurobindo Pharma Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
M Madan Mohan ReddyE D & Wholetime Director697.8Mar 26
Kambam Nityananda ReddyVice Chairman & M.D.546.9Mar 26
Girish Paman VanvariIndependent Non Exe. Director42Mar 26
Santanu MukherjeeIndependent Non Exe. Director41Mar 26
M R KumarChairman & Independent Directo37Mar 26
Satakarni MakkapatiNon-Exec & Non-Independent Dir9Mar 26
Penaka Sarath Chandra ReddyNon-Exec & Non-Independent Dir8Mar 26
Punita Kumar SinhaIndependent Non Exe. Director6.8Mar 26
P V Ramprasad ReddyNon Executive Director5Mar 26
B Adi ReddyCompany Sec. & Compli. Officer-Mar 26

Aurobindo Pharma Brands

Brands owned by Aurobindo Pharma

LOGOBRAND NAME
Rinoban
Diceta
Alfuzosin
viranz
Website: www.aurobindo.com

About the company - Business Profile

Aurobindo Pharma Limited is an integrated pharmaceutical company with a market-leading position in generics and active pharmaceutical ingredients (APIs). As the second-largest listed Indian pharmaceutical company by revenue, it operates across 150+ countries. The company is primarily focused on the development, manufacturing, and commercialization of a diverse range of medications, maintaining a status as the largest generic pharmaceutical company in the US by prescriptions dispensed. With 29 commercial manufacturing facilities and 9 R&D centers, the company maintains extensive vertical integration to manage costs and ensure supply chain reliability.

Key Points

  • Key Facts: Founded in 1986 and headquartered in Hyderabad, India, Aurobindo Pharma is listed on the BSE and NSE. It specializes in generic formulations and APIs across multiple therapeutic areas, including CNS, CVS, anti-diabetics, and oncology.
  • Operations and Resources: The company operates 29 manufacturing facilities globally. It has a formulation capacity exceeding 60 billion doses and an API capacity of 19,000 MT. Its R&D infrastructure includes 1,500+ scientists and analysts.
  • Ownership: The company is promoter-led, with significant institutional and public holdings. It has evolved from a small API manufacturer into a vertically integrated global entity.
  • Market and Significance: Aurobindo is a dominant player in the US generic market and is ranked among the top 10 generic companies in eight European countries. Its strategic importance lies in its ability to provide affordable complex therapies at scale.
  • Sustainability and Innovation: The company targets becoming a top 25 global pharma company by 2030. In FY25, it achieved a 22% reduction in carbon emissions (vs FY20 baseline) and utilized 14% renewable energy. R&D investments reached ₹1,622 crore in FY25 (up 10% YoY).
  • Business Model: Aurobindo utilizes a vertically integrated model where a significant portion of its API requirements is met through internal production. This reduces dependence on third-party suppliers and enhances margin control. It excels in large-scale manufacturing and navigating complex regulatory landscapes for ANDA filings.
  • Revenue Breakdown (FY25 Annual):
    • Total Revenue: ₹31,724 crore (19.4% growth).
    • Formulations: Contributes approximately 85% of the total revenue mix.
      • US: ₹13,867 crore (FY24 data - 48% of mix).
      • Europe: ₹7,166 crore (FY24 data - 25% of mix).
      • Growth Markets: ₹2,517 crore (9% of mix).
      • ARV: ₹868 crore (3% of mix).
    • APIs: ₹4,241 crore (FY24 data - 15% of mix).
  • Key Products and Technology:
    • Portfolio: 879 US ANDA filings as of December 2025, with 719 final approvals.
    • Biosimilars: Active development and commercialization pipeline for complex products.
    • Specialty: Focus on injectables, inhalers, and transdermals.
  • Employee Count: The global workforce exceeds 37,000 personnel, including permanent and contractual workers. Training hours per employee averaged 25 hours in FY25.
  • Major Subsidiaries: Key units include Eugia Pharma Specialities (focused on sterile injectables and oncology) and Aurobindo Pharma USA Inc.
  • Strategic Initiatives: Current focus remains on enhancing the specialty pipeline, scaling biosimilar offerings, and executing capacity expansions through a ₹2,700+ crore capex program. The company is also implementing digitisation and automation across its manufacturing ecosystem to drive operational efficiency.

References

  1. Annual Report May 2025
  2. Annual Report May 2024
  3. Investor Presentation Feb 2026
  4. Investor Presentation Feb 2026
  5. Earnings Call Nov 2025
  6. Investor Presentation Nov 2025

Aurobindo Pharma FAQ

Aurobindo Pharma today is trading in the green, up by 1.3% at ₹1,681.4.
Aurobindo Pharma is currently trading up 1.3% on an intraday basis. In the past week the stock rose 6.98%. Stock has been up 6.4% in the past quarter and rose 47.63% in the past year. You can view this in the share price history/seasonality section.
Aurobindo Pharma is listed on NSE with the ticker AUROPHARMA and on BSE as 524804. It's currently trading on NSE at a share price of ₹1,681.4 and on BSE with a share price of ₹1,677.8.
The market cap of Aurobindo Pharma is ₹97,655.98 Cr. as of Oct 30, 2026.
Aurobindo Pharma announced a INTERIM dividend of 400% which equals ₹4 in Aug 08, 2025.The last three ex-dates for Aurobindo Pharma were Feb 20, 2024, Nov 20, 2023 and Feb 17, 2023. To view the full dividend history of Aurobindo Pharma click here.
Aurobindo Pharma has undergone 2 stock splits and announced bonus shares 2 times since its BSE/NSE listing. The latest announcement for Aurobindo Pharma stock split was on Feb 10, 2011 at a ratio of 5:1 and the last bonus share announcement was on Jul 20, 2015 at a ratio of 1:1.
Aurobindo Pharma reported ₹9,414.58 Cr. in revenue, ₹1,032.56 Cr. in net profit, and ₹2,105.11 Cr. in EBITD as of Aug 05, 2026 for Q1 FY26-27.
According to the predictions of 26 analysts, the share price prediction for Aurobindo Pharma is ₹1,757.15 with an upside of 5%.
The PE ratio of Aurobindo Pharma is 24.78 as of Oct 30, 2026.
The PB ratio of Aurobindo Pharma is 2.51 as of Oct 30, 2026.
You can view the latest analyst reports on the Aurobindo Pharma reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×